Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Kristine E Fasmer, Ankush Gulati, Julie A Dybvik, Sigmund Ytre-Hauge, ��yvind Salvesen, Jone Trovik, Camilla Krakstad, Ingfrid S Haldorsen
Author Information
Kristine E Fasmer: Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, 5021, Bergen, Norway. kristine.fasmer@helse-bergen.no. ORCID
Ankush Gulati: Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, 5021, Bergen, Norway.
Julie A Dybvik: Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, 5021, Bergen, Norway.
Sigmund Ytre-Hauge: Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, 5021, Bergen, Norway.
��yvind Salvesen: Unit for Applied Clinical Research, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
Jone Trovik: Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway.
Camilla Krakstad: Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway.
Ingfrid S Haldorsen: Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Jonas Liesvei 65, 5021, Bergen, Norway.
OBJECTIVES: To compare the diagnostic accuracy of preoperative 18F-FDG PET/CT and MRI tumor markers for prediction of lymph node metastases (LNM) and aggressive disease in endometrial cancer (EC). METHODS: Preoperative whole-body 18F-FDG PET/CT and pelvic MRI were performed in 215 consecutive patients with histologically confirmed EC. PET/CT-based tumor standardized uptake value (SUV and SUV), metabolic tumor volume (MTV), and PET-positive lymph nodes (LNs) (SUV >���2.5) were analyzed together with the MRI-based tumor volume (V), mean apparent diffusion coefficient (ADC), and MRI-positive LN (maximum short-axis diameter ������10 mm). Imaging parameters were explored in relation to surgicopathological stage and tumor grade. Receiver operating characteristic (ROC) curves were generated yielding optimal cutoff values for imaging parameters, and regression analyses were used to assess their diagnostic performance for prediction of LNM and progression-free survival. RESULTS: For prediction of LNM, MTV yielded the largest area under the ROC curve (AUC) (AUC���=���0.80), whereas V had lower AUC (AUC���=���0.72) (p���=���0.03). Furthermore, MTV >���27 ml yielded significantly higher specificity (74%, p���<���0.001) and accuracy (75%, p���<���0.001) and also higher odds ratio (12.2) for predicting LNM, compared with V >���10 ml (58%, 62%, and 9.7, respectively). MTV >���27 ml also tended to yield higher sensitivity than PET-positive LN (81% vs 50%, p���=���0.13). Both V >���10 ml and MTV >���27 ml were significantly associated with reduced progression-free survival. CONCLUSIONS: Tumor markers from 18F-FDG PET/CT outperform MRI markers for the prediction of LNM. MTV >���27 ml yields a high diagnostic performance for predicting aggressive disease and represents a promising supplement to conventional PET/CT reading in EC. KEY POINTS: ��� Metabolic tumor volume (MTV) outperforms other 18F-FDG PET/CT and MRI markers for preoperative prediction of lymph node metastases (LNM) in endometrial cancer patients. ��� Using cutoff values for tumor volume for prediction of LNM, MTV >���27 ml yielded higher specificity and accuracy than V>���10 ml. ��� MTV represents a promising supplement to conventional PET/CT reading for predicting aggressive disease in EC.
